[1]
|
R. B. Raney Jr., M. Tefft, D. M. Hays and T. J. Triche, “Rhabdomyosarcoma and the Undifferentiated Sarcomas,” In: P. A. Pizzo and D. G. Poplack, Eds., Principles and Practice of Pediatric Oncology, Lippincott, Philadelphia, 1993, pp. 769-794.
|
[2]
|
R. Dagher and L. Helman, “Rhabdomyosarcoma: An Overview,” Oncologist, Vol. 4, No. 1, 1999, pp. 34-44.
|
[3]
|
I. Q. Iyad Sultan, S.Yaser, C.Rodriguez-Galindo, and A.Ferrari, “Comparing Adult and Pediatric Rhabdomyosarcoma in the Surveillance, Epidemiology and End Results Program, 1973 to 2005: An Analysis of 2,600 Patients,” Oncology & Radiotherapy, Vol. 27, No. 20, 2009, pp. 3391-3397. doi:10.1002/cncr.24424
|
[4]
|
W. M. Crist, et al., “Intergroup Rhabdomyosarcoma Study-IV: Results for Patients with Nonmetastatic Disease,” Journal of Clinical Oncology, Vol. 19, No. 12, 2001, pp. 3091-3102.
|
[5]
|
X. J. Yuan, et al., “Treatment Outcome of Rhabdomyosarcoma in Hong Kong Chinese Children,” Hong Kong Medical Journal, Vol. 14, No. 2, 2008, pp. 116-123.
|
[6]
|
A. S. Pappo, et al., “Biology and Therapy of Pediatric Rhabdomyosarcoma,” Journal of Clinical Oncology, Vol. 13, No. 8, 1995, pp. 2123-2139. doi:10.1007/BF02368677
|
[7]
|
J. L. Meza, et al., “Analysis of Prognostic Factors in Patients with Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children’s Oncology Group,” Journal of Clinical Oncology, Vol. 24, No. 24, 2006, pp. 3844-3851. doi:10.1200/JCO.2005.05.3801
|
[8]
|
D. O. Walterhouse, et al., “Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children with Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children’s Oncology Group Study,” Journal of Clinical Oncology, Vol. 22, No. 8, 2004, pp. 1398-1403. doi:10.1200/JCO.2004.05.184
|
[9]
|
F. B. Ruymann and A. C. Grovas, “Progress in the DiagNosis and Treatment of Rhabdomyosarcoma and Related Soft Tissue Sarcomas,” Cancer Investigation, Vol. 18, No. 3, 2000, pp. 223-241. doi:10.3109/07357900009031827
|
[10]
|
C. Akyuz, et al., “Turkish Experience with Rhabdomyosarcoma: An Analysis of 255 Patients for 20 Years,” The Turkish Journal of Pediatrics, Vol. 40, No. 4, 1998, pp. 491-501. doi:10.1016/S0959-8049(98)00024-0
|
[11]
|
F. Flamant, et al., “Treatment of Non-Metastatic Rhabdomyosarcomas in Childhood and Adolescence. Results of the Second Study of the International Society of Paediatric Oncology: MMT84,” European Journal of Cancer, Vol. 34, No. 7, 1998, pp. 1050-1062.
|
[12]
|
A. S. Pappo, et al., “Survival after Relapse in Children and Adolescents with Rhabdomyosarcoma: A Report from the Intergroup Rhabdomyosarcoma Study Group,” Journal of Clinical Oncology, Vol. 17, No. 11, 1999, pp. 3487-3493.
|
[13]
|
E. Koscielniak, et al., “Results of Treatment for Soft Tissue Sarcoma in Childhood and Adolescence: A Final Report of the German Cooperative Soft Tissue Sarcoma Study CWS-86,” Journal of Clinical Oncology, Vol. 17, No. 12, 1999, pp. 3706-3719.
|
[14]
|
C. A. Arndt, et al., “Vincristine, Actinomycin, and Cyclophosphamide Compared with Vincristine, Actinomycin, and Cyclophosphamide Alternating with Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children’s Oncology Group Study D9803,” Journal of Clinical Oncology, Vol. 27, No. 31, 2009, pp. 5182-5188. doi:10.1200/JCO.2009.22.3768
|
[15]
|
A. S. Pappo, et al., “Two Consecutive Phase II Window Trials of Irinotecan alone or in Combination with Vincristine for the treatment of Metastatic Rhabdomyosarcoma: The Children’s Oncology Group,” Journal of Clinical Oncology, Vol. 25, No. 4, 2007, pp. 362-369. doi:10.1200/JCO.2006.07.1720
|
[16]
|
S. L. Wolden, et al., “Indications for Radiotherapy and Chemotherapy after Complete Resection in Rhabdomyosarcoma: A Report from the Intergroup Rhabdomyosarcoma Studies I to III,” Journal of Clinical Oncology, Vol. 17, No. 11, 1999, pp. 3468-3475.
|
[17]
|
L. M. Smith, et al., “Which Patients with Microscopic Disease and Rhabdomyosarcoma Experience Relapse after Therapy? A Report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group,” Journal of Clinical Oncology, Vol. 19, No. 20, 2001, pp. 4058-4064.
|
[18]
|
S. S. Donaldson, et al., “Results from the IRS-IV Randomized Trial of Hyperfractionated Radiotherapy in Children with Rhabdomyosarcoma—A Report from the IRSG,” International Journal of Radiation Oncology, Biology, Physics, Vol. 51, No. 3, 2001, pp. 718-728.doi:10.1016/S0360-3016(01)01709-6
|
[19]
|
C, M. T. Hua and S. L. Spunt, “Early Results of a Prospective Study Delivering Limited Margin Radiotherapy for Pediatric Patients with Rhabdomyosarcoma,” International Journal of Radiation Oncology, Biology, Physics, Vol. 69, Suppl. 3, 2007, p. S37.doi:10.1016/j.ijrobp.2007.07.068
|
[20]
|
M. D. Wharam, J. M. James Anderson, J. C. Breneman, S. S. Donaldson, T. J. Fitzgerald, J. Michalski, L. A. Teot, E. S. Wiener and W. H. Meyer, “Failure Pattern and Factors Predictive of Local Failure in Rhabdomyosarcoma: A Report of Group III Patients on the Third Intergroup Rhabdomyosarcoma Study,” Journal of Clinical Oncology, Vol. 22, No. 10, 2004, pp. 1902-1908.
|
[21]
|
B. Weigel, E. Lyden J. R. Anderson, A. Galster, C. A. Arndt, J. Michalski, D. S. Hawkins and W. H. Meyer, “Early Results from Children’s Oncology Group (COG) ARST0431: Intensive Multidrug Therapy for Patients with Metastatic Rhabdomyosarcoma (RMS),” Journal of Clinical Oncology, Vol. 28, Suppl. 15, 2010, p. 9503.
|